Primary breast cancer in elderly women: biological profile and relation with clinical outcome

被引:98
作者
Daidone, MG
Coradini, D
Martelli, G
Veneroni, S
机构
[1] Ist Nazl Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy
[2] Ist Nazl Tumori, Dipartimento Med Preditt Prevent, I-20133 Milan, Italy
关键词
biomarkers; breast cancer; elderly patients; predictive factors; prognosis;
D O I
10.1016/S1040-8428(02)00144-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A biological characterisation carried out on 14007 primary breast cancers provided evidence in favour of a relation between advanced age and favourable features (positivity for oestrogen/progesterone receptors, low proliferative rate, absence of p53 accumulation, bcl-2 overexpression, diploid DNA content), showed a similar pattern of association between patho-biological variables regardless of patient age, and demonstrated a relation between biological variables and disease outcome in the elderly, comparable to that already reported for younger patients. In fact, oestrogen receptor and proliferative activity provided independent prognostic information either in node-negative or in node-positive tumours treated with radical or conservative surgery plus radiotherapy, alone or followed by adjuvant hormonal therapy. It would be thus reasonable to use biomarkers as a complement to clinico-pathological features in a 'risk-factor profile system' even for elderly patients, upon their validation in prospective studies and after assessing the cost-benefit of treatments planned on the basis of biological information. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 35 条
[1]   Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chu, KC ;
Chatterjee, N ;
Brawley, O ;
Brinton, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :18-27
[2]   Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (>=70 years of age)? [J].
Balducci, L ;
Extermann, M ;
Fentiman, I ;
Monfardini, S ;
Perrone, F .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1720-1722
[3]   CANCER INCIDENCE AND SURVIVAL IN PATIENTS 65 YEARS OF AGE AND OLDER [J].
BARANOVSKY, A ;
MYERS, MH .
CA-A CANCER JOURNAL FOR CLINICIANS, 1986, 36 (01) :26-41
[4]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[5]   ADJUVANT SYSTEMIC THERAPY FOR BREAST-CANCER IN THE ELDERLY - COMPETING CAUSES OF MORTALITY [J].
CASTIGLIONE, M ;
GELBER, RD ;
GOLDHIRSCH, A .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :519-526
[6]  
Clarke M, 1998, LANCET, V351, P1451
[7]  
Daidone M G, 2001, J Natl Cancer Inst Monogr, P27
[8]   Clinical studies of Bcl-2 and treatment benefit in breast cancer patients [J].
Daidone, MG ;
Luisi, A ;
Veneroni, S ;
Benini, E ;
Silvestrini, R .
ENDOCRINE-RELATED CANCER, 1999, 6 (01) :61-68
[9]  
Daidone MG, 2000, BRIT J CANCER, V82, P270
[10]  
DAIODONE MG, 1998, COMPREHENSIVE GERIAT, P197